Recently_RB published_VBN papers_NNS :_: New_JJ evidence_NN for_IN old_JJ debates_NNS ,_, new_JJ drugs_NNS and_CC some_DT timely_JJ reminders_NNS The_DT present_JJ article_NN provides_VBZ a_DT brief_JJ synopsis_NN from_IN the_DT past_JJ 2_CD month_NN 's_POS critical_JJ care_NN literature_NN ._SENT There_EX has_VBZ been_VBN a_DT longstanding_JJ debate_NN in_IN the_DT fields_NNS of_IN sepsis_NN and_CC multiple_JJ organ_NN dysfunction_NN syndrome_NN regarding_VBG the_DT relative_JJ importance_NN of_IN microcirculatory_JJ failure_NN versus_CC mitochondrial_JJ failure_NN ._SENT This_DT debate_NN stems_VBZ from_IN the_DT observation_NN that_IN in_IN the_DT presence_NN of_IN supranormal_JJ oxygen_NN delivery_NN there_RB is_VBZ frequently_RB a_DT failure_NN to_TO achieve_VB normal_JJ levels_NNS of_IN consumption_NN ,_, and_CC there_EX is_VBZ an_DT association_NN between_IN the_DT magnitude_NN of_IN this_DT discrepancy_NN and_CC outcome_NN ._SENT Accordingly_RB ,_, measures_NNS of_IN global_JJ oxygen_NN consumption_NN ,_, such_JJ as_IN mixed_JJ (_( or_CC central_JJ )_) venous_JJ oxygen_NN saturations_NNS ,_, plasma_NN lactate_NN and_CC base_NN deficit_NN ,_, are_VBP widely_RB considered_VBN the_DT best_JJS markers_NNS of_IN the_DT adequacy_NN of_IN resuscitation_NN ._SENT Using_VBG a_DT novel_JJ method_NN of_IN intravital_JJ microscopy_NN of_IN the_DT sublingual_JJ mucosa_NN ,_, de_NP Backer_NP and_CC colleagues_NNS have_VBP demonstrated_VBN that_IN microcirculatory_JJ perfusion_NN is_VBZ reduced_VBN by_IN ~50_JJ %_NN despite_IN normal_JJ global_JJ haemodynamic_JJ parameters_NNS ,_, and_CC that_IN shunting_VBG by_IN larger_JJR vessels_NNS is_VBZ commonplace_JJ ._SENT This_DT confirms_VBZ previous_JJ animal_NN and_CC tissue_NN studies_NNS ,_, and_CC despite_IN the_DT excellent_JJ pictures_NNS (_( see_VB )_) is_VBZ unsurprising_VBG ._SENT Of_IN note_NN ,_, the_DT authors_NNS found_VBD that_IN the_DT degree_NN of_IN severity_NN correlated_VBN with_IN the_DT outcome_NN ._SENT What_WP is_VBZ remarkable_JJ ,_, however_RB ,_, is_VBZ the_DT demonstration_NN ,_, using_VBG this_DT intravital_JJ microscopy_NN technique_NN of_IN the_DT preservation_NN of_IN local_JJ vascular_JJ responsiveness_NN to_TO the_DT vasodilatory_JJ mediator_NN acetylcholine_NN ,_, and_CC indeed_RB the_DT restoration_NN of_IN local_JJ microcirculatory_JJ function_NN achieved_VBN by_IN its_PP$ administration_NN ._SENT Whether_IN this_DT reflects_VBZ a_DT local_JJ imbalance_NN between_IN vasoconstrictors_NNS and_CC dilators_NNS remains_VBZ speculative_JJ but_CC ,_, of_IN note_NN ,_, 18_CD of_IN the_DT 21_CD patients_NNS were_VBD receiving_VBG exogenous_JJ catecholamine_NN vasopressors_NNS to_TO maintain_VB a_DT target_NN mean_VB arterial_JJ pressure_NN ._SENT Enthusiastic_JJ conclusions_NNS were_VBD drawn_VBN regarding_VBG the_DT utility_NN of_IN this_DT intravital_JJ microscopy_NN technique_NN in_IN an_DT accompanying_JJ editorial_NN ,_, and_CC a_DT proposal_NN was_VBD made_VBN that_IN semiquantitative_JJ measures_NNS of_IN the_DT sublingual_JJ microcirculation_NN be_VB added_VBN to_TO the_DT goals_NNS of_IN the_DT adequacy_NN of_IN resuscitation_NN ._SENT Intravital_NP holds_VBZ considerable_JJ promise_NN as_IN a_DT research_NN tool_NN but_CC ,_, like_IN gastric_JJ tonometry_NN ,_, its_PP$ universal_JJ application_NN appears_VBZ to_TO lack_NN foundation_NN ,_, for_IN the_DT present_NN at_IN least_JJS ._SENT In_IN a_DT complementary_JJ study_NN ,_, Brealey_NP and_CC colleagues_NNS report_NN on_IN their_PP$ investigations_NNS of_IN mitochondrial_JJ function_NN in_IN the_DT muscles_NNS of_IN patients_NNS with_IN severe_JJ sepsis_NN ._SENT They_PP found_VBD convincing_JJ evidence_NN of_IN mitochondrial_JJ failure_NN and_CC found_VBD a_DT strong_JJ correlation_NN between_IN the_DT degree_NN of_IN failure_NN and_CC adverse_JJ outcome_NN ._SENT What_WP these_DT two_CD studies_NNS demonstrate_VBP is_VBZ that_IN both_CC the_DT microcirculatory_JJ failure_NN and_CC the_DT mitochondrial_JJ failure_NN are_VBP important_JJ pathophysiological_JJ processes_NNS in_IN sepsis_NN ,_, and_CC indeed_RB it_PP seems_VBZ probable_JJ that_IN the_DT former_JJ precipitates_NNS the_DT latter_NN ._SENT What_WP makes_VBZ both_DT of_IN these_DT studies_NNS noteworthy_JJ is_VBZ that_IN they_PP represent_VBP some_DT of_IN the_DT most_RBS eloquent_JJ demonstrations_NNS of_IN these_DT processes_NNS in_IN critically_RB ill_JJ patients_NNS to_TO date_NN ._SENT Let_VB us_PP hope_VBP that_IN ongoing_JJ research_NN identifies_VBZ successful_JJ strategies_NNS to_TO modify_VB these_DT processes_NNS ._SENT One_CD such_JJ strategy_NN may_MD be_VB the_DT potentiation_NN of_IN the_DT paracrine_JJ messenger_NN adenosine_NN ,_, although_IN previous_JJ successes_NNS in_IN mice_NNS have_VBP all_RB too_RB often_RB failed_VBN to_TO translate_VB to_TO humans_NNS ._SENT Similarly_RB ,_, extrapolating_VBG the_DT observation_NN that_IN a_DT low_JJ serum_NN granulocyte_NN --_: macrophage_NN colony-stimulating_NN factor_NN is_VBZ prognostic_JJ of_IN a_DT poor_JJ outcome_NN in_IN sepsis_NN to_TO the_DT efficacy_NN of_IN exogenous_JJ supplementation_NN is_VBZ an_DT oft_RB trodden_VBN path_NN with_IN a_DT poor_JJ track_NN record_NN ._SENT Finally_RB ,_, the_DT keenly_RB awaited_VBN French_NP '_POS steroid_NN replacement_NN '_POS trial_NN in_IN sepsis_NN has_VBZ been_VBN published_VBN ._SENT The_DT first_JJ important_JJ finding_NN was_VBD a_DT very_RB high_JJ incidence_NN of_IN adrenal_JJ insufficiency_NN in_IN 229_CD of_IN the_DT 299_CD patients_NNS (_( 77_CD %_NN )_) studied_VBN ,_, albeit_IN that_DT interpreting_VBG corticotrophin_NN studies_NNS in_IN such_JJ patients_NNS is_VBZ controversial_JJ ._SENT Interestingly_RB ,_, corticotrophin_NN responsiveness_NN did_VBD not_RB predict_VB outcome_NN ._SENT Intensive_JJ care_NN unit_NN ,_, hospital_NN ,_, 28-day_JJ and_CC 1-year_JJ mortality_NN were_VBD very_RB high_JJ in_IN all_DT groups_NNS (_( 53_CD --_: 77_CD %_NN )_) ._SENT In_IN the_DT responder_NN groups_NNS ,_, randomisation_NN to_TO the_DT treatment_NN group_NN conferred_VBD no_DT benefit_NN ._SENT In_IN the_DT nonresponders_NNS ,_, treatment_NN conferred_VBD a_DT statistically_RB significant_JJ survival_NN advantage_NN to_TO 28_CD days_NNS that_WDT persisted_VBD but_CC ceased_VBD to_TO be_VB significant_JJ at_IN 1_CD year_NN (_( although_IN the_DT study_NN was_VBD not_RB powered_VBN to_TO test_VB 12-month_JJ mortality_NN )_) ._SENT There_EX were_VBD no_DT detectable_JJ adverse_JJ events_NNS associated_VBN with_IN treatment_NN ._SENT The_DT regimen_NN of_IN intravenous_JJ hydrocortisone_NN (_( 50_CD mg_NN ,_, 6_CD hourly_JJ )_) plus_CC daily_JJ enteral_JJ fluorocortisone_NN (_( 50_CD mug_NN )_) is_VBZ arguably_RB too_RB high_JJ ,_, and_CC no_DT doubt_NN future_NN studies_NNS will_MD address_VB this_DT ._SENT Annane_NP et_FW al._FW conclude_VBP by_IN advocating_VBG universal_JJ corticotrophin_NN testing_NN followed_VBN by_IN treatment_NN ,_, which_WDT should_MD be_VB withdrawn_VBN in_IN responders_NNS ._SENT There_EX has_VBZ been_VBN growing_VBG interest_NN in_IN the_DT natriuretic_NN peptides_NNS for_IN sometime_RB ._SENT July_NP saw_VBD the_DT publication_NN of_IN a_DT paper_NN by_IN Maisel_NP et_FW al._FW demonstrating_VBG the_DT diagnostic_JJ potential_NN of_IN a_DT bedside_NN assay_NN for_IN B-type_NP natriuretic_NN peptide_NN in_IN the_DT differential_JJ diagnosis_NN of_IN acute_JJ dyspnoea_NN ._SENT That_DT study_NN and_CC two_CD studies_NNS from_IN last_JJ year_NN suggest_VBP that_IN levels_NNS of_IN these_DT peptides_NNS correlate_VBP with_IN the_DT severity_NN of_IN cardiac_JJ failure_NN but_CC ,_, as_RB with_IN troponins_NNS as_IN markers_NNS of_IN myocardial_JJ damage_NN ,_, caution_NN in_IN the_DT interpretation_NN of_IN results_NNS is_VBZ likely_JJ to_TO be_VB required_VBN ._SENT On_IN the_DT subject_NN of_IN troponin_NN ,_, it_PP is_VBZ encouraging_VBG to_TO find_VB a_DT little_JJ light_NN being_VBG shed_VBN on_IN the_DT difficulties_NNS of_IN its_PP$ meaningful_JJ interpretation_NN ._SENT It_PP has_VBZ been_VBN observed_VBN that_IN troponin_NN levels_NNS are_VBP elevated_VBN in_IN the_DT presence_NN of_IN renal_JJ impairment_NN ,_, making_VBG interpretation_NN and_CC therefore_RB diagnosis_NN of_IN acute_JJ coronary_JJ syndromes_NNS difficult_JJ in_IN the_DT critically_RB ill_JJ ._SENT To_TO investigate_VB this_DT ,_, Aviles_NP et_FW al._FW studied_VBN whether_IN troponin_NN T_NN levels_NNS were_VBD predictive_JJ of_IN outcome_NN ,_, a_DT composite_NN of_IN death_NN and_CC myocardial_JJ infarction_NN within_IN 30_CD days_NNS ,_, in_IN a_DT large_JJ cohort_NN of_IN patients_NNS (_( n_NN =_SYM 7033_CD )_) with_IN suspected_JJ acute_JJ coronary_JJ syndrome_NN and_CC both_DT normal_JJ and_CC reduced_VBN creatinine_NN clearance_NN ._SENT After_IN adjustment_NN for_IN potential_JJ confounding_VBG factors_NNS ,_, an_DT abnormally_RB elevated_JJ troponin_NN T_NN level_NN (_( >0.1_JJ ng/ml_NNS )_) was_VBD found_VBN to_TO be_VB predictive_JJ of_IN myocardial_JJ infarction_NN or_CC death_NN regardless_RB of_IN renal_JJ function_NN ._SENT It_PP is_VBZ sobering_JJ to_TO be_VB reminded_VBN that_IN the_DT use_NN of_IN inodilators_NNS in_IN the_DT treatment_NN of_IN acute_JJ cardiac_JJ failure_NN has_VBZ never_RB undergone_VBN a_DT large-scale_JJ ,_, randomised_VBN ,_, controlled_VBN trial_NN ._SENT However_RB ,_, with_IN the_DT advent_NN of_IN the_DT novel_NN calcium-sensitising_VBG agent_NN levosimendan_NN ,_, one_CD such_JJ trial_NN has_VBZ now_RB been_VBN reported_VBN ._SENT This_DT trial_NN randomised_VBD 2003_CD patients_NNS with_IN acute_JJ or_CC acute_JJ on_IN chronic_JJ heart_NN failure_NN to_TO receive_VB 24_CD hours_NNS of_IN either_DT dobutamine_NN or_CC levosimendan_NN ._SENT A_DT higher_JJR proportion_NN of_IN those_DT patients_NNS who_WP received_VBD levosimendan_NN (_( 29_CD %_NN versus_IN 15_CD %_NN )_) achieved_VBN target_NN improvements_NNS in_IN haemodynamic_JJ parameters_NNS ._SENT More_RBR impressively_RB ,_, a_DT lower_JJR proportion_NN of_IN these_DT patients_NNS died_VBD over_IN the_DT following_VBG 6_CD months_NNS (_( 26_CD %_NN versus_IN 38_CD %_NN )_) ._SENT Although_IN cardiogenic_JJ shock_NN and_CC multiorgan_NN failure_NN were_VBD exclusion_NN criteria_NNS in_IN this_DT trial_NN ,_, it_PP surely_RB provides_VBZ evidence_NN to_TO justify_VB similar_JJ studies_NNS in_IN critically_RB ill_JJ patients_NNS with_IN low_JJ cardiac_JJ output_NN ._SENT On_IN a_DT related_JJ point_NN ,_, a_DT thought-provoking_VBG if_IN methodologically_RB suboptimal_JJ study_NN of_IN the_DT significant_JJ association_NN between_IN the_DT administration_NN of_IN dopamine_NN and_CC the_DT incidence_NN of_IN delirium_NN will_MD hopefully_RB result_VB in_IN a_DT more_RBR thorough_JJ examination_NN of_IN the_DT neuropsychiatric_JJ sequelae_NNS of_IN all_PDT the_DT commonly_RB used_VBN doperminergic_NN drugs_NNS ._SENT On_IN a_DT final_JJ cardiac_JJ note_NN ,_, the_DT encouraging_JJ results_NNS of_IN a_DT trial_NN of_IN ibutilide_NN as_IN second-line_NN therapy_NN in_IN the_DT treatment_NN of_IN atrial_JJ fibrillation_NN in_IN the_DT critically_RB ill_JJ suggests_VBZ that_IN this_DT novel_NN class_NN III_NP anti-arrhythmic_NP may_MD provide_VB a_DT much_JJ needed_JJ treatment_NN for_IN this_DT common_JJ condition_NN ,_, which_WDT all_RB too_RB often_RB proves_VBZ difficult_JJ to_TO control_VB ._SENT Attention_NN to_TO simple_JJ details_NNS is_VBZ as_RB important_JJ ,_, if_IN not_RB more_JJR ,_, than_IN complex_NN and_CC novel_NN interventions_NNS ._SENT A_DT semirecumbant_NN or_CC upright_JJ posture_NN has_VBZ been_VBN repeatedly_RB demonstrated_VBN to_TO result_VB in_IN superior_JJ respiratory_JJ and_CC overall_JJ outcome_NN ._SENT Despite_IN these_DT demonstrations_NNS ,_, however_RB ,_, the_DT implementation_NN of_IN this_DT intervention_NN appears_VBZ to_TO be_VB poor_JJ ._SENT Cook_NP and_CC colleagues_NNS have_VBP published_VBN a_DT timely_JJ survey_NN on_IN this_DT issue_NN ._SENT They_PP conclude_VBP that_IN a_DT classic_JJ case_NN of_IN system_NN failure_NN exists_VBZ with_IN regard_NN to_TO patient_JJ positioning_NN ,_, and_CC they_PP suggest_VBP a_DT number_NN of_IN useful_JJ strategies_NNS to_TO overcome_VB this_DT and_CC similar_JJ problems_NNS ._SENT At_IN the_DT other_JJ extreme_NN of_IN patient_JJ positioning_NN ,_, the_DT study_NN by_IN Lee_NP et_FW al._FW suggests_VBZ that_IN instigating_VBG the_DT prone_JJ position_NN early_RB in_IN the_DT course_NN of_IN acute_JJ lung_NN injury_NN to_TO patients_NNS with_IN a_DT larger_JJR shunt_NN and_CC a_DT more_RBR compliant_JJ chest_NN wall_NN predicts_VBZ success_NN ._SENT Their_PP$ study_NN contributes_VBZ further_RBR confirmatory_JJ evidence_NN of_IN the_DT clinical_JJ benefit_NN of_IN prone_JJ positioning_NN but_CC does_VBZ nothing_NN to_TO answer_VB the_DT vital_JJ questions_NNS regarding_VBG how_WRB long_JJ patients_NNS should_MD be_VB in_IN the_DT prone_JJ position_NN for_IN maximum_JJ benefit_NN ,_, and_CC indeed_RB whether_IN improving_VBG gas_NN exchange_NN translates_VBZ into_IN better_JJR outcomes_NNS ._SENT Against_IN the_DT advancing_VBG wave_NN of_IN enthusiasm_NN for_IN face_NN mask_NN positive_JJ pressure_NN ventilation_NN (_( NIPPV_NP )_) ,_, a_DT significant_JJ negative_JJ study_NN has_VBZ been_VBN published_VBN ._SENT The_DT authors_NNS randomised_VBD a_DT heterogeneous_JJ group_NN of_IN patients_NNS who_WP developed_VBD respiratory_JJ distress_NN within_IN 48_CD hours_NNS of_IN extubation_NN to_TO receive_VB standard_JJ therapy_NN or_CC standard_JJ therapy_NN plus_IN NIPPV_NP ._SENT They_PP found_VBD no_DT benefit_NN from_IN this_DT intervention_NN ._SENT To_TO their_PP$ credit_NN ,_, the_DT authors_NNS acknowledge_VBP that_IN more_JJR experienced_JJ units_NNS or_CC targeting_VBG specific_JJ patient_JJ groups_NNS might_MD have_VB achieved_VBN a_DT positive_JJ outcome_NN ,_, but_CC they_PP conclude_VBP that_IN they_PP cannot_MD recommend_VB NIPPV_NP as_IN an_DT intervention_NN in_IN this_DT setting_NN ._SENT We_PP would_MD argue_VB from_IN both_DT personal_JJ experience_NN and_CC trial_NN evidence_NN that_IN NIPPV_NP in_IN this_DT setting_NN can_MD prevent_VB the_DT need_NN to_TO reintubate_NNS ,_, and_CC that_IN a_DT trial_NN of_IN NIPPV_NP is_VBZ sometimes_RB warranted_VBN ,_, not_RB least_RBS as_IN a_DT failed_JJ trial_NN is_VBZ unlikely_JJ to_TO harm_VB the_DT patient_NN ._SENT Ventilator-associated_JJ pneumonia_NN remains_VBZ a_DT major_JJ cause_NN of_IN morbidity_NN and_CC mortality_NN ._SENT The_DT optimal_JJ diagnostic_JJ technique_NN is_VBZ controversial_JJ ,_, with_IN some_DT studies_NNS suggesting_VBG that_IN invasive_JJ methods_NNS improve_VBP outcome_NN while_IN others_NNS have_VBP been_VBN unable_JJ to_TO demonstrate_VB any_DT benefit_NN from_IN these_DT expensive_JJ and_CC time-consuming_JJ investigations_NNS ._SENT To_TO further_VB this_DT debate_NN ,_, Wu_NP and_CC colleagues_NNS have_VBP compared_VBN quantitative_JJ culture_NN of_IN endotracheal_JJ aspirates_NNS ,_, protected_VBN specimen_NN brushings_NNS and_CC bronchoalveolar_JJ lavage_NN to_TO investigate_VB whether_IN bacteriological_JJ findings_NNS correlated_VBN in_IN patients_NNS with_IN suspected_JJ ventilator-associated_JJ pneumonia_NN ._SENT They_PP demonstrated_VBD that_IN the_DT less_RBR invasive_JJ and_CC less_RBR work-intensive_JJ technique_NN of_IN quantitative_JJ culture_NN of_IN endotracheal_JJ aspirates_NNS correlated_VBD well_RB with_IN both_DT protected_VBN specimen_NN brushings_NNS and_CC bronchoalveolar_JJ lavage_NN findings_NNS ,_, allowing_VBG early_JJ definitive_JJ antibiotic_JJ choice_NN or_CC cessation_NN of_IN antibiotics_NNS in_IN the_DT case_NN of_IN negative_JJ results_NNS ._SENT Criticism_NN of_IN their_PP$ investigation_NN might_MD include_VB the_DT small_JJ study_NN number_NN and_CC lack_NN of_IN any_DT outcome_NN benefit_NN demonstrated_VBD ,_, although_IN this_DT was_VBD not_RB the_DT aim_NN of_IN the_DT study_NN ._SENT However_RB ,_, a_DT significant_JJ impediment_NN to_TO this_DT approach_NN is_VBZ the_DT inability_NN to_TO obtain_VB routine_JJ quantitative_JJ cultures_NNS in_IN many_JJ hospitals_NNS ._SENT With_IN mounting_VBG evidence_NN in_IN favour_NN of_IN quantitative_JJ assessment_NN of_IN specimens_NNS ,_, this_DT problem_NN may_MD need_VB addressing_VBG ._SENT Magnesium_NN is_VBZ known_VBN to_TO be_VB a_DT bronchodilator_NN and_CC has_VBZ been_VBN anecdotally_RB reported_VBN as_IN having_VBG beneficial_JJ effects_NNS in_IN acute_JJ severe_JJ asthma_NN ._SENT However_RB ,_, these_DT findings_NNS have_VBP not_RB been_VBN consistently_RB reproduced_VBN in_IN well_RB designed_VBN ,_, randomised_VBN ,_, controlled_VBN trials_NNS ._SENT In_IN a_DT welcome_JJ attempt_NN to_TO address_VB this_DT issue_NN ,_, Silverman_NP and_CC colleagues_NNS have_VBP conducted_VBN such_PDT a_DT trial_NN and_CC found_VBD that_IN the_DT addition_NN of_IN intravenous_JJ magnesium_NN to_TO standard_JJ therapy_NN resulted_VBN in_IN a_DT significant_JJ improvement_NN in_IN FEV1_NP ,_, at_IN 4_CD hours_NNS ,_, in_IN those_DT with_IN the_DT most_RBS severe_JJ airway_NN obstruction_NN (_( baseline_JJ FEV1_NN <_SYM 25_CD %_NN predicted_VBN )_) ._SENT Given_VBN that_DT magnesium_NN is_VBZ safe_JJ and_CC inexpensive_JJ ,_, and_CC that_IN there_EX is_VBZ now_RB good_JJ evidence_NN to_TO support_VB its_PP$ routine_JJ use_NN in_IN the_DT severest_JJS cases_NNS ,_, it_PP only_RB remains_VBZ for_IN the_DT optimal_JJ dose_NN and_CC duration_NN of_IN therapy_NN to_TO be_VB established_VBN ._SENT Nasogastric_JJ feeding_NN is_VBZ found_VBN to_TO be_VB at_IN least_JJS as_RB good_JJ as_RB ,_, if_IN not_RB better_JJR than_IN ,_, nasojejunal_JJ feeding_NN in_IN the_DT hands_NNS of_IN Neumann_NP and_CC DeLegge_NP ,_, essentially_RB because_IN nasojejunal_JJ tube_NN placement_NN results_NNS in_IN a_DT significant_JJ delay_NN in_IN the_DT start_NN of_IN feeding_NN ._SENT Surely_RB the_DT pragmatic_JJ approach_NN is_VBZ to_TO start_VB with_IN a_DT nasogastric_JJ tube_NN and_CC to_TO only_RB employ_VB the_DT alternatives_NNS in_IN cases_NNS of_IN failure_NN ._SENT The_DT long-term_JJ success_NN of_IN renal_JJ allografts_NNS from_IN nonheart-beating_VBG donors_NNS is_VBZ reported_VBN by_IN Weber_NP and_CC colleagues_NNS ._SENT Sadly_RB ,_, adoption_NN of_IN this_DT technique_NN ,_, in_IN the_DT UK_NP at_IN least_JJS ,_, awaits_VBZ the_DT deliberation_NN of_IN the_DT government_NN and_CC judiciary_NN ._SENT Finally_RB ,_, if_IN you_PP have_VBP been_VBN seduced_VBN by_IN the_DT attractive_JJ qualities_NNS of_IN alcohol-based_JJ hand_NN rubs_VBZ to_TO reduce_VB crossinfection_NN while_IN avoiding_VBG hand_NN washing_NN ,_, then_RB be_VB warned_VBN :_: your_PP$ gel_NN may_MD not_RB be_VB all_PDT its_PP$ cracked_VBN up_RP to_TO be_VB ._SENT In_IN addition_NN to_TO the_DT aforementioned_JJ studies_NNS ,_, we_PP would_MD also_RB recommend_VB the_DT following_VBG commentaries_NNS and_CC reviews_NNS ._SENT None_NN declared_VBD ._SENT FEV1_NN =_SYM forced_JJ expiratory_JJ volume_NN in_IN 1_CD second_NN ;_: NIPPV_NP =face_NNS mask_VBP positive_JJ pressure_NN ventilation_NN ._SENT 